CanariaBio

CanariaBio is a biotechnology company specializing in the development of new anti-cancer drugs, possessing research assets for the development of immune anti-cancer therapeutics. Through its subsidiaries, it has a pipeline for the development of various immune anti-cancer treatments targeting ovarian cancer, pancreatic cancer, and metastatic breast cancer. Starting from the second half of 2020, FLORA-5 (Oleclumab) officially entered Phase III global clinical trials with the U.S. FDA for the treatment of ovarian cancer. FLORA-5 (Oleclumab) demonstrated outstanding results in Phase II clinical trials and gained attention through the publication in the Global Journal of Gynecological Oncology.